Security key
49372L209
Kezar Life Sciences, Inc. - Common Stock (KZR)
CUSIP: 49372L209
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 7,437,095
- Total 13F shares
- 18,300
- Share change
- +18,300
- Total reported value
- $10,980
- Price per share
- $0.60
- Number of holders
- 1
- Value change
- +$10,980
- Number of buys
- 1
Report period
Q2 2024
Institutions
1
Top holders
1
KZR full security history
Newer quarter: Q3 2024
Kezar Life Sciences, Inc. SEC filings
Kezar Life Sciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 49372L209
Recent filing periods:
Top shareholders of KZR - Kezar Life Sciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
97%
|
7,167,591
|
$6,462,300 | — | 31 Mar 2024 | |
| Avidity Partners Management LP |
13F
|
Company |
68%
|
5,026,000
|
$4,531,442 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
62%
|
4,616,988
|
$4,162,677 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
42%
|
3,094,224
|
$2,789,753 | — | 31 Mar 2024 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
28%
|
2,051,676
|
$1,849,791 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
26%
|
1,927,000
|
$1,737,383 | — | 31 Mar 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
24%
|
1,790,838
|
$1,613,000 | — | 31 Mar 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
24%
|
1,761,778
|
$1,588,419 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
19%
|
1,373,689
|
$1,238,643 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
18%
|
1,338,074
|
$1,206,000 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
18%
|
1,302,254
|
$1,174,112 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
17%
|
1,231,800
|
$1,110,591 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
15%
|
1,123,774
|
$1,013,195 | — | 31 Mar 2024 | |
| Prosight Management, LP |
13F
|
Company |
13%
|
963,598
|
$868,780 | — | 31 Mar 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
12%
|
868,992
|
$783,484 | — | 31 Mar 2024 | |
| Qiming U.S. Ventures Management, LLC |
13F
|
Company |
11%
|
828,711
|
$747,166 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
11%
|
816,973
|
$736,583 | — | 31 Mar 2024 | |
| Acuitas Investments, LLC |
13F
|
Company |
9.3%
|
690,829
|
$622,851 | — | 31 Mar 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
9.3%
|
688,943
|
$621,151 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
7%
|
515,363
|
$464,651 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
6.9%
|
509,564
|
$459,423 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
5.7%
|
419,425
|
$378,153 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
5.5%
|
404,706
|
$364,883 | — | 31 Mar 2024 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
4.7%
|
350,394
|
$315,915 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
4.3%
|
314,762
|
$283,789 | — | 31 Mar 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
3.8%
|
282,595
|
$255,000 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
3.8%
|
279,265
|
$251,339 | — | 31 Mar 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
3.7%
|
273,430
|
$246,524 | — | 31 Mar 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
3.2%
|
236,623
|
$213,339 | — | 31 Mar 2024 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
3.2%
|
233,206
|
$210,259 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
3.1%
|
226,490
|
$204,203 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
2.9%
|
214,264
|
$193,181 | — | 31 Mar 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
2%
|
150,485
|
$135,677 | — | 31 Mar 2024 | |
| Marquette Asset Management, LLC |
13F
|
Company |
1.7%
|
126,095
|
$113,688 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
1.5%
|
109,435
|
$98,701 | — | 31 Mar 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
108,600
|
$97,914 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
101,151
|
$91,198 | — | 31 Mar 2024 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
100,801
|
$90,882 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
1.2%
|
89,700
|
$80,873 | — | 31 Mar 2024 | |
| Amundi |
13F
|
Individual |
1.1%
|
82,243
|
$64,775 | — | 31 Mar 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.1%
|
79,058
|
$71,279 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.97%
|
71,509
|
$64,501 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.72%
|
53,316
|
$48,070 | — | 31 Mar 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.72%
|
53,216
|
$47,980 | — | 31 Mar 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.68%
|
50,118
|
$45,186 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.64%
|
47,674
|
$43,000 | — | 31 Mar 2024 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.48%
|
35,172
|
$31,711 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.45%
|
33,249
|
$29,958 | — | 31 Mar 2024 | |
| OCCUDO QUANTITATIVE STRATEGIES LP |
13F
|
Company |
0.43%
|
31,769
|
$28,643 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.41%
|
30,464
|
$27,466 | — | 31 Mar 2024 |
Institutional Holders of Kezar Life Sciences, Inc. - Common Stock (KZR) as of Q2 2024
As of 30 Jun 2024,
Kezar Life Sciences, Inc. - Common Stock (KZR) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
18,300 shares.
The largest 1 holders included
Catalyst Funds Management Pty Ltd.
This page lists
1
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q4 2025 Across Filers
Q4 2025 holders
43
Q2 2024 holders
1
Holder diff
-42
| Investor | Q4 2025 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.